Trials Keep Climbing as AI Tightens
The cure stack keeps widening: 21,170 active cure-related trials are now in motion, while 78 new pieces of cure research and 64 new wire signals landed in the last 24 hours. On the science side, post-marketing safety work on ustekinumab in Crohn’s disease extended the evidence base, Insilico nominated ISM9077 as a preclinical candidate for ocular, inflammatory, and aging indications, and Galibra secured FDA orphan and rare pediatric disease designations for its SSADH deficiency gene therapy. On the systems side, the AI layer is hardening at the same time—Anthropic made Claude Opus 5 the default for most coding and agent workloads, and the EU gave itself new enforcement powers over model makers. The pattern is clear: more shots on goal in biomedicine, while AI becomes both more capable and more governed. The window is still open.
In the last 24 hours, the wire logged 21,170 active cure-related trials, 78 new cure research items, and 64 new intelligence signals.
The gains accrue to patients, researchers, and platforms that can turn AI and data control into faster drug discovery, while the pressure falls on model makers and regulators as capability scales into oversight.
Watch whether AI defaults, infrastructure spend, and EU enforcement translate into faster, safer biological discovery before the next wave of preclinical and clinical milestones closes in.